Plasmodium malariae malaria

Summary

Plasmodium malariae malaria (MONDO:0001943) is a disease. A subtype of malaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Plasmodium malariae malaria
Mondo ID	MONDO:0001943
DOID	DOID:14324
ICD-10-CM	B52
NCIT	C34799
SNOMED CT	27618009
UMLS	C0024536
MedGen	44259
GARD	0023043
Is cancer (heuristic)	no

Also known as: quartan malaria

Disease family

This is a subtype of malaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › malaria › Plasmodium malariae malaria

Related subtypes (6): Plasmodium ovale malaria, mixed malaria, cerebral malaria, blackwater fever, Plasmodium falciparum malaria, Plasmodium vivax malaria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.